Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1633 1642 1644 1646 1647
This examiner grants 58% of resolved cases
Peter J. Reddig serves as an examiner in Tech Center 1600 and Art Unit 1633. He has a total of 1039 resolved cases. The allowance rate for these cases is 57.9 percent. This 57.9 percent rate indicates the frequency at which applications reach a grant under his review. With 1039 resolved cases, the profile provides a specific look at the outcomes in this docket.
The interview lift is 40.2 percent. This 40.2 percent figure is lower than the 57.9 percent allowance rate, but it represents a significant increase in the likelihood of allowance for cases that include an interview. Practitioners in Art Unit 1633 may use this 40.2 percent lift to evaluate the impact of direct communication. The median days to allowance is 1255. This 1255-day duration is the typical timeframe for successful applications. The 1255-day metric, combined with the 1039 resolved cases, helps stakeholders understand the pendency and probability of success in Tech Center 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18106531 | Methods for Reducing Infusion-Related Reactions in Patients Treated with EGFR/Met Bispecific Antibodies | Final Rejection | Janssen Biotech, Inc. |
| 17784891 | METHOD AND COMPOSITION FOR ENHANCING THE IMMUNE RESPONSE | Non-Final OA | Northwestern University |
| 18514836 | CHIMERIC NANOBODY COMPOSITIONS AND METHODS OF TREATMENT THEREOF | Non-Final OA | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK |
| 18420525 | TARGETING CYTOTOXIC CELLS WITH CHIMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY | Non-Final OA | The Trustees of the University of Pennsylvania |
| 18339565 | CD20 THERAPIES, CD22 THERAPIES, AND COMBINATION THERAPIES WITH A CD19 CHIMERIC ANTIGEN RECEPTOR (CAR)-EXPRESSING CELL | Final Rejection | The Trustees of the University of Pennsylvania |
| 18274118 | PREVENTION OF POSTERIOR CAPSULAR OPACIFICATION (PCO) WITH INTEGRIN AVB8 BLOCKING ANTIBODY | Non-Final OA | UNIVERSITY OF DELAWARE |
| 18342884 | PEPTIDE ANALOGS CAPABLE OF ENHANCING STIMULATION OF A GLIOMA-SPECIFIC CTL RESPONSE | Non-Final OA | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 18418804 | GENERATION AND PROFILING OF FULLY HUMAN THERAPEUTIC ANTIBODIES SPECIFIC FOR HUMAN CD38 | Non-Final OA | MORPHOSYS AG |
| 18500706 | COMBINATION THERAPIES FOR TREATMENT OF BCMA-RELATED CANCERS AND AUTOIMMUNE DISORDERS | Non-Final OA | Fred Hutchinson Cancer Center |
| 18373648 | ANTI-PD-1/LAG-3 BISPECIFIC ANTIBODIES AND USES THEREOF | Non-Final OA | Incyte Corporation |
| 18511817 | CHIMERIC APOPTOTIC SIGNAL TARGETING LYMPHOCYTES (TIM-4 CASTL) AND METHODS OF MAKING AND USING SAME | Non-Final OA | Duke University |
| 17328953 | VACCINES AGAINST ANTIGENS INVOLVED IN THERAPY RESISTANCE AND METHODS OF USING SAME | Non-Final OA | Duke University |
| 17289877 | T CELLS FROM LYMPHATIC FLUID FOR DIAGNOSTIC AND THERAPEUTIC USE | Non-Final OA | THE CHILDREN'S HOSPITAL OF PHILADELPHIA |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy